<DOC>
	<DOCNO>NCT00425529</DOCNO>
	<brief_summary>The primary objective clinical trial test tolerance practicality new device Module AOX . The secondary objective determine change oxidative , antioxidative status , plasma free amino acid , various immune parameter critically ill patient receive enteral nutrition without use Module AOX .</brief_summary>
	<brief_title>Tolerance Practicality Module AOX</brief_title>
	<detailed_description>Surgery trauma induce hypercatabolism accompany systemic immunoinflammtory response massive production reactive oxygen specie site injury . In situation , requirement certain amino acid ( glutamine , cysteine ) antioxidant micronutrient ( zinc , vitamin E , vitamin C , beta-caroteen , selenium ) markedly increase may cover level normally present standard enteral diet , especially early phase enteral nutrition introduce gradually . Thus , supplementation amino acid antioxidant micronutrient may appropiate order optimize nutritional support patient . The administration select nutrient via modular device add standard enteral formulation attractive mean provide optimize nutrition support specific disease state . Module AOX intend supplementation patient require nutritional support condition oxidative stress expect . The module contain : - Glutamine : support gut mucosal immune function , minimize early depletion glutamine store preserve body protein - Cysteine : support synthesis glutathione , important cellular antioxidant , support synthesis acute phase proteins - Vitamin E , vitamin C beta-caroteen : water- lipid-soluble antioxidant micronutrient boost antioxidant defense - Zinc : compensate increase loss support protein synthesis , immune function wound heal - Selenium : compensate increase loss , support antioxidant defense immune function</detailed_description>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<criteria>patient undergo major surgery esophagus , stomach pancreas patient eligible jejunostomy feeding age &gt; 18 &lt; 75 BMI &lt; 35 obtain his/her his/her legal representative 's informed consent patient history main cardiovascular kidney disease weigth loss &gt; 10 % last 6 month patient receive corticosteroid , investigational drug , last 6 weekd prior surgery patient HIV infection patient participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>